Branded and generic meloxicam tablet products had U.S. sales of approximately $105 million in the third quarter of 2006.
Taro Pharmaceutical Industries (Nasdaq: TARO) reported today that it has received approval from the U.S. Food and Drug Administration (`FDA') for its Meloxicam tablets, 7.5 mg and 15 mg.
Taro's meloxicam tablets are used for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. This new Taro prescription product is bioequivalent to Boehringer Ingelheim's Mobic tablets. According to industry sources, branded and generic meloxicam tablet products had U.S. sales of approximately $105 million in the third quarter of 2006.
Taro also reported today that it has received tentative approval from the FDA for its for Cetirizine Hydrochloride Syrup, 1 mg/mL. This is a generic version of Pfizer Inc.'s (NYSE: PFE; LSE: PFZ) Zyrtec syrup. Zyrtec syrup is a prescription product used for treating allergic rhinitis and chronic urticaria (hives).
Published by Globes [online], Israel business news - www.globes.co.il - on November 9, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006